Core Viewpoint - Altria is highlighted as a strong dividend stock with a yield of 6.3%, supported by a solid financial history and recent stock price appreciation, making it an attractive investment option despite concerns about its tobacco business [1][2][4]. Group 1: Dividend Performance - Altria's forward dividend is $4.24, and it has increased its dividend 55 times over the past 55 years, totaling $32 billion in dividends paid from 2020 to 2024 [1][3]. - The company has also repurchased $8 billion of its shares during the same period, indicating a commitment to returning value to shareholders [3]. Group 2: Stock Price and Market Comparison - Altria's share price has risen 27% since the beginning of the year, outperforming the S&P 500, which is up 10% [2]. - In contrast, competitors like Pfizer and Dow have seen declines in their stock prices, with Pfizer down 8% and Dow down 37% this year [3]. Group 3: Financial Performance - In the latest quarter, Altria reported a revenue decline of 6% to $5.3 billion, but its adjusted diluted EPS increased by 6% to $1.23, with guidance for a 2% to 5% increase in EPS for the full year [4]. - The company's performance is attributed to its traditional tobacco business, which remains profitable despite market challenges [4]. Group 4: Economic Resilience - Altria's dividend is considered safe, as consumers typically do not reduce cigarette consumption during economic downturns, suggesting stability in its revenue stream [5]. - The potential economic risks, such as increased tariffs and inflation, may further solidify Altria's position as a preferred stock for investors seeking reliable dividends [6][7].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (QMCO) for securities fraud, affecting investors who purchased shares between November 15, 2024, and August 18, 2025 [1][2]. Group 1: Events Leading to the Lawsuit - On June 30, 2025, Quantum announced it would not be able to file its annual financial report on time due to a review of its accounting related to revenue contracts, resulting in a stock price drop of $1.00, or 10.03%, closing at $8.97 per share [3]. - On August 8, 2025, Quantum stated that its third quarter 2024 financial statements should no longer be relied upon due to material weaknesses in internal controls, leading to a revenue restatement of approximately $3.9 million [4]. - Following this announcement, Quantum's stock fell by $0.14, or 1.79%, to close at $7.66 per share on August 11, 2025 [5]. - On August 18, 2025, the resignation of Quantum's CEO after five months in the position caused the stock to drop by $0.61, or 8.2%, closing at $6.83 per share on August 19, 2025 [5]. Group 2: Allegations in the Lawsuit - The lawsuit alleges that throughout the Class Period, Quantum made materially false and misleading statements and failed to disclose adverse facts about its business and operations [6]. - Specific allegations include improper revenue recognition during the fiscal year ended March 31, 2025, necessitating a restatement of previously filed financial statements for the fiscal third quarter ended December 31, 2024 [6][7]. - The lawsuit claims that the positive statements made by Quantum regarding its business lacked a reasonable basis and were materially misleading [7].

Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to alleged securities fraud, with a significant stock price drop following the company's revision of its revenue and EBITDA guidance for 2025 [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA due to temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price fell by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and operations during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in its RexMD segment [3]. - The lawsuit claims that positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period are encouraged to file a lead plaintiff motion by October 27, 2025 [4]. - The law firm Glancy Prongay & Murray LLP is leading the class action and is available for inquiries regarding participation [5][6].

Core Viewpoint - Semler Scientific Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding its QuantaFlo device and reimbursement claims [2][4]. Summary by Sections Company Background - Semler Scientific Inc. (NASDAQ: SMLR) is involved in the development of medical devices, specifically the QuantaFlo device for peripheral artery disease [2]. Legal Developments - On February 28, 2025, Semler disclosed a potential risk of a civil lawsuit from the DOJ regarding its reimbursement claims, which led to a significant drop in its stock price [2][3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler announced on April 15, 2025, an agreement in principle to pay $29.75 million to settle all claims, resulting in another decline in stock price [3]. Stock Performance - After the February 28 announcement, Semler's stock fell by $4.03, or 9.4%, closing at $38.89 on March 3, 2025 [3]. - Following the April 15 announcement, the stock dropped by $3.40, or 9.9%, closing at $31.00 on April 16, 2025 [3]. Allegations in the Lawsuit - The class action lawsuit alleges that Semler made materially false and misleading statements and failed to disclose a DOJ investigation into violations of the False Claims Act, which misled investors about the company's business prospects [4].

Core Viewpoint - Centene Corporation is facing a securities fraud class action lawsuit due to significant revenue declines and misleading statements made by the company during the class period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Centene made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Centene's stock price dropped by $22.87, or 40.4%, closing at $33.78 per share on July 2, 2025, following the announcement of the withdrawal of its 2025 financial guidance [2]. - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025, with a deadline of September 8, 2025, for investors to seek lead plaintiff status [4]. Group 2: Financial Impact - The revenue decline was attributed to a risk-sharing mechanism related to the Affordable Care Act marketplace, which showed lower-than-expected enrollment and increased market morbidity [2][3]. - The preliminary analysis indicated that over two-thirds of Centene's marketplace share was affected, leading to the misleading nature of the company's previous positive statements [3].

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Air Lease Corporation to a consortium including Sumitomo Corporation, SMBC Aviation Capital, Apollo, and Brookfield, focusing on whether the offered price of $65.00 per share adequately reflects the company's value [1]. Group 1 - The proposed transaction involves Air Lease Corporation shareholders receiving $65.00 in cash for each share they own [1]. - Kahn Swick & Foti, LLC aims to assess the adequacy of the sale price and the process leading to this valuation [1][2]. - The investigation is prompted by concerns that the transaction may undervalue Air Lease Corporation [1].

Group 1 - The core viewpoint of the article highlights a significant breakthrough in a new polyurethane recycling process developed by Dow and Gruppo Fiori, which allows for the recovery of polyurethane materials from scrapped vehicles without disassembly [2][3] - The new process ensures that the purity of the waste material meets the requirements for chemical depolymerization, enabling the production of recycled polyols for new products [2] - Dow has previously made strides in the chemical recycling of polyurethane foam from scrapped vehicles, achieving a closed-loop recycling breakthrough in collaboration with Jaguar Land Rover and Adient, incorporating 20% recycled polyols into new automotive seat products [2] Group 2 - The waste material for this recycling process originates from second-hand polyurethane seat foams from Jaguar Land Rover, which are reprocessed into seat foam by Dow's MobilityScience™ material innovation [3] - Currently, Jaguar Land Rover is fully utilizing this material in its automotive seats and is conducting large-scale testing in pre-production vehicles [3] Group 3 - Dow's chemical recycling technology includes an amine-based depolymerization process that breaks down waste polyurethane into high-concentration dispersions of polyurethanes, ureas, amines, and polyols [4] - This method can recover various polyurethane foams, and the recycled polyols can be reused in multiple polyurethane materials, with up to 30% of recycled polyols being reintegrated into reaction injection molded (RIM) parts [4]

Group 1 - The global butadiene market outlook for the four months after 2025 is pessimistic due to increased supply from refinery maintenance season ending and new facilities coming online, leading traders to seek to shift goods from Europe and the US to higher-priced Asia [1] - Despite a decline in global butadiene prices this year, an arbitrage window has opened, prompting European goods to shift towards Asia, exacerbated by the restart of TotalEnergies' butadiene facility in France and the resumption of Dow's plant in Germany [1] - The price difference between Rotterdam and the Chinese market for butadiene in the first half of 2025 is projected to be $270.50 per ton, although Asian butadiene prices will remain the highest globally [1] Group 2 - The price spread between butadiene and naphtha may narrow as the Asian market weakens, with the spread expected to decrease from $641.17 per ton in the first half of 2025 to $400 per ton in the second half [2] - With the end of refinery maintenance season, US butadiene supply is expected to increase in the second half of 2025, although limited export opportunities due to low overseas prices will keep most of the supply in the domestic market [2] - The European butadiene market is expected to remain sluggish until the fourth quarter, with traders closely monitoring shipments to Asia, and a slow recovery in demand anticipated after buyers return from holidays in early September [2]

Core Viewpoint - The global butadiene market outlook for the four months post-2025 is pessimistic, driven by increased supply from new facilities and the end of refinery maintenance seasons [1][2] Group 1: Market Dynamics - The butadiene market is experiencing downward pressure on prices due to a surge in supply, with traders seeking to shift cargo from Europe and the US to higher-priced Asian markets [1] - Despite a decline in global butadiene prices this year, an arbitrage window has opened, prompting European shipments to Asia [1] - The price differential between Rotterdam and the Chinese market for butadiene is projected at $270.50 per ton for the first half of 2025 [1] Group 2: Supply and Demand Factors - New butadiene production facilities in Asia, such as the 140,000 tons/year facility by Lotte Chemical in Indonesia and ExxonMobil's new ethylene complex in Huizhou, are expected to further pressure the market [1] - The anticipated increase in US butadiene supply in the second half of 2025 is due to the end of refinery maintenance, with at least two shipments expected each quarter [2] - The average price of butadiene in the US Gulf Coast for the first half of 2025 is reported at 43.88 cents per pound, a 15.7% decrease from the second half of 2024 [2] Group 3: Regional Market Trends - The European butadiene market is expected to remain weak through the fourth quarter, with traders closely monitoring shipments to Asia [2] - Internal demand in Europe continues to be sluggish, despite several downstream facilities planning maintenance [2] - A slow recovery in butadiene demand is anticipated after buyers return from holidays in early September, but overall market weakness is expected to persist due to ongoing global supply pressures [2]

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for alleged misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the Class Period from January 30, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its financial flexibility and dividend support [5]. - It is alleged that Dow Inc. failed to disclose the true extent of competitive pressures, declining global sales, and product oversupply, leading to materially false public statements [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering significant settlements [4]. - Investors are advised to select qualified legal counsel with proven experience in similar cases to ensure effective representation [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion by October 28, 2025, to represent the class in the lawsuit [1][3].